Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial

Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial

User Photo
kidneycancer

2 years
179 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
Up Next Autoplay
>